Evidence map›Paper›PMID 37906510›Full record

ArticleCancer biology & therapy2023

Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing.

Yuxue Xia, Lu Zhang, Wenjuan He, Huaxiong Pan, Jun Fang, Guohui Cui

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yuxue XiaInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.ORCID 0000-0002-7203-1952
Lu ZhangInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wenjuan HeInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Huaxiong PanDepartment of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jun FangInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Guohui CuiInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Union Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsLymphoma, B-CellAnaplastic Lymphoma KinaseCarbazolesCell Cycle ProteinsClathrin Heavy ChainsCrizotinibCyclin-Dependent KinasesDNA-Binding ProteinsDrug Resistance, NeoplasmHigh-Throughput Nucleotide SequencingHumansMutationOncogene ProteinsProtein Kinase InhibitorsAnaplastic Lymphoma KinaseCarbazolesCDK14 protein, humanCell Cycle ProteinsClathrin Heavy ChainsCLTC protein, humanCrizotinibCyclin-Dependent KinasesDNA-Binding ProteinsMFHAS1 protein, humanOncogene ProteinsProtein Kinase InhibitorsTOR Serine-Threonine KinasesALKCDK14CLTCcrizotiniblarge B-cell lymphomaMFHAS1

Identifiers

PMID37906510
PMCPMC10761012
OpenAlexW4388041986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.